1. Nanotechnology describes technological developments on the 0.1 to 100 nm scale, with nanomedicine as a branch of nanotechnology that involves developing medicine on a molecular scale. In healthcare, it can be used for diagnosis, prevention and treatment of disease in addition to tissue and organ regeneration.
2. Nanomedicine develops over several years and is based on dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, naoemulsions, quantum dots and nanorobots.
3. North America dominated the nanotechnology market in 2013 and is expected to continue its position in the near future. The Asian Pacific market is expected to grow at the fastest rate due to its extensive geriatric population and growing awareness of healthcare.
4. Drivers of the nanomedicine market include:
• Improved regulatory framework
• Increased technological development and research funding
• Rising government support
• Increase in chronic disease
• High unmet medical needs
5. The risks associated with nanomedicine could include toxicity and high cost.
6. The key players in the nanomedicine market include Abbott Laboratories, CombiMatrix Corp., GE Healthcare, Sigma-Tau Pharmaceuticals, Johnson & Johnson, Mallinckrodt, Merck & Company, Nanosphere, Phizer, Celegene, Teva Pharmaceuticals, UCB.
More articles on medical devices:
Stryker, Mazor & more: 10 device company key notes
22 spine devices receive FDA 510(k) clearance in November 2016
What’s the future of global joint repair market: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
